Biblio
Export 330 results:
Author Title [ Type
Filters: First Letter Of Keyword is T [Clear All Filters]
“Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.”, J Alzheimers Dis, vol. 101, no. s1, pp. S129-S140, 2024.
, “Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.”, J Alzheimers Dis, vol. 101, no. s1, pp. S129-S140, 2024.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 797-807, 2016.
, “Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges.”, J Alzheimers Dis, vol. 49, no. 3, pp. 617-31, 2016.
, “Tobacco Smoke Exposure Impairs Brain Insulin/IGF Signaling: Potential Co-Factor Role in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 2, pp. 373-86, 2016.
, “Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 1, pp. 133-48, 2016.
, “Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 1, pp. 133-48, 2016.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.”, J Alzheimers Dis, vol. 49, no. 2, pp. 353-63, 2016.
, “The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration.”, J Alzheimers Dis, vol. 49, no. 2, pp. 399-405, 2016.
, “Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors.”, J Alzheimers Dis, vol. 98, no. 2, pp. 343-360, 2024.
, “Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors.”, J Alzheimers Dis, vol. 98, no. 2, pp. 343-360, 2024.
, “Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia.”, J Alzheimers Dis, vol. 98, no. 2, pp. 361-372, 2024.
, “Vascular Risk Factors and Cognition in Parkinson's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 563-70, 2016.
,